Featured Research

from universities, journals, and other organizations

Glass Researchers Getting A Bead On Liver Cancer

Date:
August 9, 2000
Source:
University Of Missouri-Rolla
Summary:
A method for treating liver cancer with tiny radioactive glass beads, developed by a UMR researcher and a researcher at the University of Missouri-Columbia, has been approved for use in the United States.

A method for treating liver cancer with tiny radioactive glass beads, developed by a UMR researcher and a researcher at the University of Missouri-Columbia, has been approved for use in the United States.

Delbert E. Day, Curators' Professor Emeritus of ceramic engineering at UMR, is the co-inventor of this method. The U.S. Federal Drug Administration approved Day's treatment method for use in the United States in February.

The first patients to be treated with radioactive glass beads, now marketed under the name TheraSphere by MDS Nordion, will take place later this year at the Mayo Clinic in Rochester, Minn., and at the University of Pittsburgh School of Medicine.

The treatment consists of injecting millions of tiny, radioactive glass beads into the main artery supplying blood to the liver. The blood carries the beads into the liver, where they deliver localized radiation to malignant cells in liver tumors.

"Healthy tissue is virtually unaffected, the radiation can be safely delivered, and side effects are minimal," Day says.

Microspheres smaller than a strand of hair

The beads, or microspheres, are 15 to 35 microns in diameter -- "about half the thickness of a human hair," Day says. The beads are made from a special aluminosilicate glass that contains yttrium oxide, a rare-earth element. When the glass beads are placed inside a nuclear reactor for serval days, the yttrium becomes radioactive. The radioactive beads are then injected into the liver, where they irradiate the liver for a period of 3-4 weeks, after which they are no longer radioactive but remain in the liver indefinitely.

Day, who joined the UMR faculty in 1961, and co-inventor Gary J. Ehrhardt of the University of Missouri-Columbia, started their research on the glass beads in 1982. Their first patent was granted in 1988, and since that time they have been granted a total of six U.S. patents and eight foreign patents.

Helping bones to heal

More recently, Day has turned his research efforts toward finding new ways for doctors to treat severely broken bones by using glass pins and surgical sutures to treat those breaks.

Day became interested in glass and its countless uses while a student in ceramic engineering at UMR. "I became interested in the properties and many uses of glass as an undergraduate student at UMR," he says. "I took a course in glass and as a result of that class I prepared a paper and presented it in a student speaking contest at an American Ceramic Society meeting. From then on I had an interest in glass research."


Story Source:

The above story is based on materials provided by University Of Missouri-Rolla. Note: Materials may be edited for content and length.


Cite This Page:

University Of Missouri-Rolla. "Glass Researchers Getting A Bead On Liver Cancer." ScienceDaily. ScienceDaily, 9 August 2000. <www.sciencedaily.com/releases/2000/08/000807072233.htm>.
University Of Missouri-Rolla. (2000, August 9). Glass Researchers Getting A Bead On Liver Cancer. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2000/08/000807072233.htm
University Of Missouri-Rolla. "Glass Researchers Getting A Bead On Liver Cancer." ScienceDaily. www.sciencedaily.com/releases/2000/08/000807072233.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins